Insulet Q3 FY25: where the revenue came from and where it went
The whole income statement of Insulet for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2025
- Reported
- Nov 6, 2025
Revenue$0.71B
+30% year over year
Gross profit$0.51B
72% margin
Operating profit$0.12B
17% margin
Net profit$0.09B
12% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 0.71 | 100% | +30% |
| U.S.Omnipod | 0.50 | 70% | +26% |
| International omnipod | 0.20 | 29% | +47% |
| Drug delivery | 0.01 | 1% | −31% |
| Cost of revenue | −0.20 | 28% | |
| Gross profit | 0.51 | 72% margin | +3pp |
| R&D | −0.08 | 11% | +1pp |
| SG&A | −0.32 | 45% | +2pp |
| Operating profit | 0.12 | 17% margin | +0pp |
| Other income, net | 0.01 | ||
| Tax | −0.04 | ||
| Net profit | 0.09 | 12% margin | −2pp |
129 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest